Gene Therapy Fast Tracked for APOE4 Associated Alzheimer Disease
The investigational adeno-associated virus mediated gene therapy is being developed to deliver the protective APOE2 gene to the CNS.
Alzheimer Disease and Dementia
Donanemab Studied in Early Symptomatic Alzheimer Disease
Slightly less cognitive and functional decline seen with donanemab versus placebo at 76 weeks in phase 2 trial
Dexmedetomidine Oral Film Gets Breakthrough Tx Status for Acute Agitation With Dementia
BXCL501 is an oral thin film formulation of dexmedetomidine, a selective alpha-2a receptor agonist.
FDA Extends Review of Aducanumab for Alzheimer Disease
Aducanumab, a human monoclonal antibody, binds to aggregated β-amyloid and promotes removal of amyloid from the brain.
MPR Weekly Dose Podcast Episode 65
On this week’s MPR pod we take a look at the current status of Johnson & Johnson’s COVID-19 vaccine candidate; Considerations in assessing blood donors during pandemic times; A newly approved drug to treat heart failure; Promising results for a potential Alzheimer treatment; And changes declared for vinca alkaloid labeling.
Experimental Drug for Alzheimer Disease Shows Promise
After six to 12 months of treatment with the drug, patients no longer had amyloid protein plaques.
MPR Weekly Dose Podcast Episode 58
Major developments in COVID-19 vaccine and antibody treatments: Are we close to having a vaccine gain Emergency Use Authorization? An NIH study concluded that hydroxychloroquine has no clinical benefit; And unrelated to COVID, but still big news, the Advisory Committee have voted on what would-be the first Alzheimer disease treatment in decades.
MPR Weekly Dose Podcast Episode 45
It’s been an important week with big developments in potential COVID-19 vaccines; News on how steroid therapy may help some COVID patients; There’s results from the Actemra trial in COVID pneumonia patients; News that sputum samples may be just as effective as nasopharyngeal samples for detecting SARS-CVv-2; And researchers have linked vaccination to reduced risks of Alzheimer disease.
Vaccination Linked to Reduced Alzheimer Disease Risk
At AAIC 2020, 2 presentations separately discussed observing a reduced risk of AD in patients who received the influenza and pneumonia vaccines.
Novel Therapy for Alzheimer Disease Agitation Gets Breakthrough Designation
The FDA has granted Breakthrough Therapy designation to AXS-05 (Axsome Therapeutics) for the treatment of Alzheimer disease (AD) agitation.
